Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Oxyquinoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.78 |
| ▸ | TSHR | P16473 | 2/20 | 0.78 |
| ▸ | METAP2 | P50579 | 2/20 | 0.78 |
| ▸ | METAP1 | P53582 | 2/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | COMT | P21964 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4A | O75164 | 2/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxyquinoline SCHEMBL4465896 | 1.00 | MMP2 (0.78) | MMP2TSHRMETAP2METAP1CHRM1 | |
| Oxyquinoline SCHEMBL15568316 | 0.98 | MMP2 (0.75) | MMP2TSHRMETAP2METAP1CHRM1 | |
| Oxyquinoline SCHEMBL5965842 | 0.94 | MMP2 (0.81) | MMP2TSHRMETAP2METAP1CHRM1 | |
| Oxyquinoline SCHEMBL27553390 | 0.93 | MMP2 (0.78) | MMP2TSHRMETAP2METAP1CHRM1 | |
| Oxyquinoline SCHEMBL28459062 | 0.92 | MMP2 (0.84) | MMP2TSHRMETAP2METAP1CHRM1 | |
| Oxyquinoline SCHEMBL866498 | 0.91 | MMP2 (0.75) | MMP2TSHRMETAP2METAP1CHRM1 | |
| Oxyquinoline SCHEMBL28315442 | 0.91 | MMP2 (0.81) | MMP2TSHRMETAP2METAP1CHRM1 | |
| Oxyquinoline SCHEMBL28042473 | 0.91 | MMP2 (0.81) | MMP2TSHRMETAP2METAP1CHRM1 | |
| Oxyquinoline SCHEMBL27477171 | 0.91 | MMP2 (0.81) | MMP2TSHRMETAP2METAP1CHRM1 | |
| Oxyquinoline SCHEMBL28191778 | 0.90 | TSHR (0.95) | MMP2TSHRMETAP2METAP1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-1506214-B1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARM INC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2009-12-31 | — | — | US | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7129221-B2 | 6,11-bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-7064110-B2 | 6-11 bicycle ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20050282758-A1 | 6-11 Bicyclic ketolide derivatives | NIU DEQIANG | 2005-12-22 | — | — | US | disclosed |
| US-20050159370-A1 | 6-11 Bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2005-07-21 | — | — | US | disclosed |
| EP-1509538-A1 | 6,11 BICYCLIC ERYTHROMYCIN DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20050037982-A1 | 6-11 Bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1506214-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040157787-A1 | 6-11 Bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040053861-A1 | 6,11-Bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2003097659-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003095466-A1 | 6,11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| EP-1272500-A2 | PROCESS FOR PREPARING 6-O-ALKENYL-SUBSITUTED ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6437106-B1 | ALKYLATION WITH ALKENYL CARBONATE OR CARBAMATE IN PRESENCE OF PALLADIUM CATALYST AND PHOSPHINE; CYCLIZATION | ABBOTT LABORATORIES | 2002-08-20 | — | — | US | disclosed |
| WO-2000078773-A2 | PROCESS FOR PREPARING 6-O-ALKENYL-SUBSTITUTED ERYTHROMYCIN DERIV ATIVES | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | AKR1C2, AKR1C3, AKR1C1 | MMP2 1833/4885TSHR 4172/4885METAP2 3785/4885 |
| US-20040053861-A1 | 6,11-Bicyclic erythromycin derivatives | ABCB11, CYP2B6, CYP2D6 | MMP2 1555/4885TSHR 3410/4885METAP2 2628/4885 |
| US-20050282758-A1 | 6-11 Bicyclic ketolide derivatives | AKR1C2, AKR1C3, AKR1C1 | MMP2 1833/4885TSHR 4172/4885METAP2 3785/4885 |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | MMP2 1833/4885TSHR 4172/4885METAP2 3785/4885 |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | MMP2 1833/4885TSHR 4172/4885METAP2 3785/4885 |
| US-20050037982-A1 | 6-11 Bicyclic ketolide derivatives | AKR1C2, AKR1C3, AKR1C1 | MMP2 1833/4885TSHR 4172/4885METAP2 3785/4885 |
| US-20040157787-A1 | 6-11 Bicyclic ketolide derivatives | AKR1C2, AKR1C3, AKR1C1 | MMP2 1782/4885TSHR 4083/4885METAP2 3792/4885 |
| US-20050159370-A1 | 6-11 Bicyclic ketolide derivatives | AKR1C2, AKR1C3, AKR1C1 | MMP2 1833/4885TSHR 4172/4885METAP2 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.